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intra- and extracellular β-amyloid 
overexpression via adeno-
associated virus-mediated 
gene transfer impairs memory 
and synaptic plasticity in the 
hippocampus
Stefania forner  1, Alessandra c. Martini  1, G. Aleph prieto1, cindy t. Dang1, 
carlos J. Rodriguez-ortiz  6, Jorge Mauricio Reyes-Ruiz5, Laura trujillo-estrada1, 
celia da cunha1, elizabeth J. Andrews1, Jimmy phan1, Jordan Vu Ha1, Allissa V. Z. D. chang1, 
Yona Levites4, pedro e. cruz4, Rahasson Ager1, Rodrigo Medeiros  1,7, Masashi Kitazawa6, 
charles G. Glabe5, carl W. cotman1,2,3, todd Golde4, David Baglietto-Vargas  1,2,8 & 
frank M. Laferla1,2,8*
Alzheimer’s disease (AD), the most common age-related neurodegenerative disorder, is currently 
conceptualized as a disease of synaptic failure. Synaptic impairments are robust within the AD brain and 
better correlate with dementia severity when compared with other pathological features of the disease. 
nevertheless, the series of events that promote synaptic failure still remain under debate, as potential 
triggers such as β-amyloid (Aβ) can vary in size, configuration and cellular location, challenging data 
interpretation in causation studies. Here we present data obtained using adeno-associated viral (AAV) 
constructs that drive the expression of oligomeric Aβ either intra or extracellularly. We observed that 
expression of Aβ in both cellular compartments affect learning and memory, reduce the number of 
synapses and the expression of synaptic-related proteins, and disrupt chemical long-term potentiation 
(cLTP). Together, these findings indicate that during the progression AD the early accumulation of Aβ 
inside neurons is sufficient to promote morphological and functional cellular toxicity, a phenomenon 
that can be exacerbated by the buildup of Aβ in the brain parenchyma. Moreover, our AAV constructs 
represent a valuable tool in the investigation of the pathological properties of Aβ oligomers both in vivo 
and in vitro.
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder, afflicting approximately 
5.5 million individuals in the USA and with a new case developing every 66 seconds1. The pathophysiologic 
mechanisms of AD begin long before symptom onset provides an opportunity to apply advanced imaging and 
biomarker methods to diagnose individuals during the preclinical stages of neurodegeneration. All AD brains are 
characterized by two main hallmarks: plaques, consisting of extracellular deposits of β-amyloid (Aβ), and tangles, 
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aggregates of hyperphosphorylated tau2. A fundamental mechanism in AD pathogenesis is synapse failure3,4, and 
several studies suggest that Aβ oligomers can interact with different proteins, ultimately leading to synapse tox-
icity, alterations in long-term potentiation (LTP), and cognitive impairments5–8. Also, significant synaptic loss is 
already observed in patients with mild cognitive impairment (MCI), and progressive loss is the most robust hall-
mark that correlates with cognitive decline in AD9,10. However, the underlying molecular mechanisms that impair 
the synaptic function, and cause their loss at early stages of the disease, are poorly understood. Dendritic spines 
are specialized anatomical structures in neuronal cells that serve as the postsynaptic component for the vast 
majority of CNS synapses, and are major sites of processing and storage of information in the brain2. Structural 
changes at dendritic spines underlie learning and memory processes in the brain, and alterations in spine struc-
ture and function might lead to cognitive impairments4.
A continuing debate is whether intra- or extracellular Aβ is more deleterious to the brain. It is known that 
intraneuronal Aβ accumulation occurs early in adult life in basal forebrain cholinergic neurons, increasing with 
both aging and AD in the presence of intermediate and large oligomeric states11. The early intraneuronal accumu-
lation has also been observed in transgenic rats McGill-R-Thy1-APP, which harbor the human APP751 transgene 
with the Swedish and Indiana mutations under the control of the murine Thy1.2 promoter12. In these animals, the 
intraneuronal pathology was due to a mixture of APP, CTFs and a considerable amount of Aβ, leading to deleteri-
ous effects in the CNS before amyloid plaques develop. Alternatively, additional studies suggest that intraneuronal 
Aβ precedes plaques in brain areas affected early in the disease13, is associated with synaptic deficits14, and can be 
secreted in a prion-like manner15. There is evidence of the accumulation of extracellular Aβ in an age-dependent 
manner16. Exogenous oligomers accumulate particularly at synaptic spines, and presynaptic sites can also be 
targeted17. However, as plaques correlate poorly with AD-related dementia and little is known about the effects of 
intracellular Aβ on cognitive function, we asked whether these two distinct accumulation sites could have differ-
ent effects on the development of pathology.
Several animal models of AD employ an approach based on the overexpression of mutant human amyloid precur-
sor protein (APP) or presenilin to increase Aβ expression18. Although these have been very useful and are still funda-
mental to the understanding of AD development, increasing the expression of Aβ42 via AAV-mediated gene transfer 
has been demonstrated useful in developing AD animal models19,20. In this study, we used this method to overexpress 
Aβ42 oligomers in mouse hippocampus and neuronal cultures and to analyze their effect in synaptic function and 
cognitive impairments. Overall, our findings reveal a faster yet physiologically relevant model that show that synaptic 
impairment and cognitive decline initiates as soon as Aβ accumulates in the intracellular compartment in AD.
Results
characterization of Aβ expression following incubation and injection of AAV-BRi-Aβ42 and 
AAV-UBi-Aβ42 vectors. The detailed description of generating AAV constructs used here was reported 
previously19–21. AAV vectors encoding BRI-Aβ cDNAs, fusions between human Aβ peptides and the BRI protein 
(known to be associated with amyloid deposition in British familial dementia), are able to promote high-level 
expression of Aβ peptide in the absence of APP overexpression19. AAV-BRI-Aβ42 and AAV-UBI-Aβ42 were 
created to facilitate the expression of extracellular and intracellular Aβ, respectively22.
Prior to in vivo testing, we incubated hippocampal neuronal cell cultures with AAV constructs encoding 
BRI-Aβ42 or UBI-Aβ42 fusion proteins in order to determine the optimal concentration and efficacy for each 
construct. Exogenous synthetic oligomers of Aβ were used as a positive control. We detected significant levels of 
Aβ42 in the culture medium using three concentrations of BRI-Aβ42, in contrast to the UBI-Aβ42 and EGFP 
control AAV constructs (Fig. 1a). We also measured the expression of Aβ oligomers in cell media and lysate of cell 
cultures. There is no significant increase in the cell media after incubation of either AAV constructs, even though 
there is an increased trend in the AAV-BRI-Aβ42 in accordance with what has been observed in Fig. 1a. We 
observed an increase in the levels of oligomers in the cell lysate after incubation with AAV-BRI-Aβ42 compared 
to EGFP (Fig. 1c). With these results we confirmed the ability of these constructs to promote the overexpression 
of Aβ peptides.
Next, we tested the AAV-BRI-Aβ42 and AAV-UBI-Aβ42 expression in vivo by determining the Aβ42 relative 
levels in the soluble and insoluble fractions of mice hippocampus after AAVs injection. Mice were divided into 3 
cohorts: AAV-BRI-Aβ42-treated, AAV-UBI-Aβ42-treated or AAV-EGFP-treated. Each subject received bilateral 
intrahippocampal injection of a single specific AAV construct, and the brains were collected and analyzed 3 
months later. The overexpression of BRI-Aβ42 construct resulted in higher expression of both soluble and insol-
uble Aβ42 as compared to the UBI-Aβ42 construct, while there was no detectable Aβ following EGFP incubation 
(Fig. 2a,b). Immunostaining for 6E10 in the BRI-Aβ42 construct demonstrated a high amyloid deposition in the 
hippocampus. However, animals that received the UBI-Aβ42 presented distinct neuronal processes staining with 
mild intraneuronal accumulation of Aβ (Fig. 2c), without accumulation of Aβ deposits23.
Hippocampal Aβ expression promoted by AAV constructs leads to impaired cognition. Animals 
treated with both Aβ AAV constructs presented significant cognitive impairment, measured by performance in 
the Morris Water maze test (Fig. 3). In this evaluation, both groups took more time to find the hidden platform – 
as demonstrated by latency (Fig. 3b) – and also crossed the platform fewer times (Fig. 3c). The injection of both 
vectors did not affect motor skills, as demonstrated by velocity and distance evaluation (Fig. 3d,e). These results 
are significant and demonstrate the importance of both intra- and extracellular Aβ in the development of spatial 
cognitive impairments. There are no significant changes with contextual fear conditioning (Fig. 3f).
In vitro synaptic function is altered by both BRi-Aβ42 and UBI-Aβ42. As Aβ is known to cause den-
dritic spine density and synaptic function changes24, we next examined if the cognitive impairments observed in 
our animals were associated with functional or structural changes in dendritic spines or specific synaptic markers. 
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To determine possible mechanisms by which the AAV-driven expression of Aβ42 could impair cognition, we 
evaluated the effect of BRI-Aβ42 and UBI-Aβ42 expression on long-term potentiation (LTP), the best-known 
cellular correlate of memory25. We used FASS-LTP, a flow cytometry-based method that quantifies surface GluA1 
expression in isolated synaptosomes following chemical LTP (cLTP)26–28. Synaptosomal cLTP is based on applica-
tion of the NMDA receptor co-agonist glycine, which facilitates NMDA receptor activation29. By flow-cytometry, 
FASS-LTP selectively and reliably identifies synaptosomal particles (subset of particles of ~1.0 μm) 
Figure 1. Expression of Aβ by AAV-BRI-Aβ42 and AAV-UBI-Aβ42 in hippocampal neuronal cell cultures. 
(a) Total Aβ42 levels in the media after AAV constructs incubation. AAV-BRI-Aβ42: [1] 4.7 × 1010 genome 
particles/ml, [2] 9.3 × 1010 genome particles/ml, and [3] 2.8 × 1011 genome particles/ml. AAV-UBI-Aβ42: [1] 
1.5 × 1010 genome particles/ml, [2] 7.7 × 1010 genome particles/ml, [3] 4.6 × 1011 genome particles/ml. AAV-
BRI-Aβ42 [1] and [2] promoted a 37-fold and 465-fold increase and AAV-UBI-Aβ42 [3] promoted an 18-fold 
increase in Aβ42 levels when compared to those elicited by EGFP. In comparison to AAV-BRI-Aβ42 [2], the 
concentration [3] promoted a 3-fold decrease in the levels of Aβ42. Compared to EGFP, Aβ 10 mM elicited a 
669-fold increase (*p < 0.0001). (b) No significant change was observed in Aβ42 oligomers in the cell media 
after incubation of either AAV constructs. (c) AAV-BRI-Aβ42 promoted a significant increase in the levels of 
Aβ42 oligomers in the cell lysate compared to EGFP (*p < 0.0001).
Figure 2. Expression of Aβ by AAV-BRI-Aβ42 and AAV-UBI-Aβ42 in mice hippocampus. (a,b) Both soluble 
and insoluble fractions of the mouse hippocampus show an increase in Aβ42 levels after AAV-BRI-Aβ42 or 
AAV-UBI-Aβ42 transfection (*p < 0.0001). (c) Light microscopy images of the hippocampus (CA1 region) 
immunostained with anti-Aβ antibody (6E10) of ntg mice treated with EGFP, AAV-BRI-Aβ42 or AAV-
UBI-Aβ42.
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using calibrated beads (Fig. 4a,b), and quantifies potentiated synaptosomes by extracellular labeling of the AMPA 
receptor subunit GluA1 and neurexin-1β (Nrx1β)26,27, a presynaptic adhesion molecule stabilized at the mem-
brane surface by synaptic activity30. GluA1 and Nrx1β double-labeling ensures the analysis of intact synaptosomes 
that contain both pre- and postsynaptic elements. In synaptosomes of mice treated with the control AAV-EGFP 
vector, cLTP stimulation increased the proportion of synaptosomes expressing both GluA1 and Nrx1β at the sur-
face (GluA1 + Nrx1β+), relative to non-stimulated synaptosomes (basal condition, Fig. 4d). In contrast, the levels 
of potentiated GluA1 + Nrx1β+ synaptosomes were similar in the basal and cLTP conditions in the BRI-Aβ42 
and UBI-Aβ42 groups (P > 0.05, Fig. 3d), thereby indicating that both BRI-Aβ42 and UBI-Aβ42 impair LTP 
mechanisms directly at the synapse.
Both BRi-Aβ42 and UBI-Aβ42 drive synapse loss in vivo. Consistent with the suppression of syn-
aptosomal cLTP by BRI-Aβ42 and UBI-Aβ42, we found that our AAV constructs reduced the total number of 
spines (Fig. 5a), as well as that of stable mushroom spines (Fig. 5b). The BRI-Aβ42 construct also significantly 
reduced stubby (Fig. 5c) and filopodia-like spines (Fig. 5d), whereas the UBI-Aβ42 construct did not affect the 
stubby spines, i.e. there was a higher number of these immature spines in this group. In addition, we observed 
reduced protein levels of the pre- and postsynaptic markers PSD-95 and synaptophysin, respectively (Fig. 5f,g), 
as well as of profilin-1 (Fig. 5h), an actin cytoskeleton protein, suggesting that impairments in synaptic function 
and strength could be related to intra- and extracellular Aβ.
Discussion
The findings of this study imply that intra- and extracellular Aβ accumulation mediated by AAV-gene transfer can 
promote deleterious effects on synaptic and cognitive functions. Our study indicates that these AAV constructs 
of Aβ42 induce memory impairments, alongside reductions in the number of spines and of proteins related to 
synaptic function and LTP. These results are significant as they demonstrate that mild intraneuronal accumulation 
of Aβ42 (UBI-42) is as potent as combined intraneuronal and extracellular accumulation (BRI-42), significantly 
impacting our understanding of the detrimental aspects of AD.
The view that insoluble Aβ fibrils are the major factor in AD pathogenesis was firmly held until prefibrillar 
soluble Aβ oligomers were shown to be more detrimental in some experimental settings31–35. These oligomers can 
interact with glutamate receptors, dysregulating calcium influx and also altering spine morphology and density36. 
Moreover, when extracted directly from AD brains and injected into rodent brains, they can inhibit LTP, enhance 
long-term depression (LTD), and reduce dendritic spine numbers37. Although the potential role of extracellular 
Aβ oligomers is more well-established, there is also evidence that intracellular Aβ and its deposition precede the 
formation of plaques in animal models and human brains38. We observed a significant increase in both soluble 
Figure 3. Aβ AAV-mediated gene transfer impair cognition and LTP in ntg mice. (a) Mice were trained on the 
spatial reference version of the Morris water maze at 8–9 months of age. Acquisition curves for the 5 days of 
training show significant differences in groups treated with AAV-BRI-Aβ42 and AAV-UBI-Aβ42 compared to 
EGFP (*p < 0.0001). (b) Animals in the AAV-BRI-Aβ42 and AAV-UBI-Aβ42 groups had an increase in the latency 
to reach the hidden platform compared to EGFP group (175.82% ± 20.86 and 156.00% ± 20.13, respectively; 
*p = 0.0127). (c) A significant decrease in frequency was observed in the AAV-BRI-Aβ42 and AAV-UBI-Aβ42 
groups (30.22% ± 9.49 and 36.06% ± 3.58, respectively; *p = 0.0016). (d) No differences were observed between 
groups in distance or velocity behavior. Values represent the mean ± S.E.M (n = 10 per group).
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Figure 4. AAV-BRI-Aβ42 and AAV-UBI-Aβ42 induce functional, morphological, and structural synaptic 
alterations. (a) Flow cytometry FASS-LTP identifies synaptosomes by size. Based on calibrated beads, we set a 
threshold in the forward scatter (FSC-H) channel, as well as a gate region. We excluded small particles having 
a size equivalent to 0.5 µm calibrated beads (red particles), while selecting particles of ~ 1.0 µm calibrated 
beads (blue particles). (b) Forward-Side (FSC-SSC) profile of particles in the synaptosomal P2 fraction 
isolated from the hippocampus. The inside rectangle (gate) selects putative synaptosomes according with to 
size (~1.0 µm = size-gated synaptosomes). (c) In size-gated synaptosomes, FASS-LTP identifies potentiated 
synapses by tracking GluA1 and Nrx1β surface staining. To induce cLTP in samples from each experimental 
group (EGFP, AAV-BRI-Aβ42 and AAV-UBI-Aβ42 samples were run in parallel), synaptosomal P2 fractions 
maintained in Mg2+ -free external solution were sequentially stimulated using 500 µM glycine (15 min) 
and 37 mM KCl (30 min). As controls, equivalent volumes of external solution were added to a parallel set of 
synaptosomal fractions maintained in external solution (basal). Representative two-color parameter plots show 
GluA1 (x-axis) and Nrx1β (y-axis) surface levels in basal and cLTP conditions. Thresholds for endogenous/
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and insoluble fractions of Aβ, particularly with the BRI-Aβ42 construct. Moreover, this construct also induced 
the formation of plaques as well as intraneuronal accumulation of Aβ in the CA1 area of the hippocampus.
The first reports describing the existence of intracellular Aβ appeared shortly after the original identification of 
Aβ as the main component of plaques. Since then, other studies have provided evidence for intracellular Aβ accu-
mulation in transgenic mouse brain and in post-mortem brain samples from AD and Down syndrome patients. 
A rat model with a doubly mutated APP, driven by a Thy1.2 promoter highly expressed in neurons, triggered the 
accumulation of intraneuronal human Aβ in 2–3-month-old rats, coinciding with cognitive impairments and 
pre-plaque generation39. Further evidence linking intraneuronal Aβ accumulation to cognitive deficits and syn-
aptic dysfunction came from transgenic mouse models38,40–42. However, the overexpression of specific genes and 
the subsequent formation of plaques and/or tau pathology in such models make it hard to attribute the associated 
cognitive impairments they promote exclusively to the presence of intracellular Aβ. Our results are significant 
because, through the promotion of both intra- and extracellular Aβ, we can conclude that the accumulation of Aβ 
peptides, even in young mice, is sufficient to promote behavioral and synaptic impairments.
Synaptic deficits and loss are the pathological hallmarks that best correlate with the progressive cogni-
tive decline observed in AD patients43–45. Here, we have demonstrated that synaptic function as measured by 
FASS-LTP is affected very early. We used FASS-LTP, an approach to evaluate chemically-induced LTP directly in 
isolated synaptosomes. FASS-LTP identifies the subset of synaptosomes that are double-labeled for surface GluA1 
and Nrx1β (GluA1 + Nrx1β +). Importantly, the increase in surface GluA1 + Nrx1β+ levels after cLTP stimu-
lation is sustained, and mechanistically parallels the facilitation of synaptic transmission following electrically 
induced LTP (e.g., dependence on NMDAR and CaMKII), as previously shown26,27. Specifically, the generation 
of cLTP was reduced significantly in the presence of either intra- and extracellular Aβ. Our results are in accord-
ance with recent findings, whereas LTP was blocked by the intracellular injection of Aβ42 into hippocampal 
pyramidal cells46, and by extracellular Aβ at the CA3-CA1 synapses of APP-knockout mice47. Moreover, the 
Aβ42-induced impairment of glutamatergic synaptic function is dependent on its internalization and intracellu-
lar accumulation48.
Information storage underlying learning and memory, as well as signal transduction at excitatory synapses, 
develop at the postsynaptic density (PSD)49,50. Within PSDs, the most abundant scaffolding protein is PSD-95, 
which is known to play key roles in synaptic plasticity51,52. In the pre-synapse, the loss of synaptophysin is one of 
the best brain correlates of cognitive decline in AD53, occurring early in the development of disease and accom-
panied by increased APP and hyperphosphaorylated tau expression in neurons of the hippocampus and entorhi-
nal cortex54. Interestingly, the reduction in synaptic density is more pronounced within immature and mature 
plaques55. Moreover, the actin cytoskeleton and its dynamics play pivotal roles in modulating synaptic function 
by organizing the PSD, anchoring postsynaptic receptors, facilitating the trafficking of synaptic cargoes, and local-
izing the translation machinery in the synapses56,57. Therefore, impairments in signaling pathways that regulate 
synaptic markers such as PSD-95 and synaptophysin, and actin dynamics, such as profilin-1, could lead to the 
synaptic and cognitive deficits observed early in AD.
Dendritic spines are specialized anatomical structures in neuronal cells that serve as the postsynaptic element/
component for the vast majority of CNS synapses. Structural changes at dendritic spines underlie learning and mem-
ory processes in the brain, and changes in spine structure and function might lead to cognitive impairments. Spines 
can be classified morphologically into four types: stubby, mushroom, thin and filopodia-like, which corresponds 
to their maturation and function as immature, stable and mature, transient or lacking synapses, respectively58,59. 
The structure and function of dendritic spines are dynamically regulated by cellular pathways acting on the actin 
cytoskeleton. In the data reported here, we observed that an increase in Aβ42 both intra- and extracellularly was 
coupled with a reduction in important synaptic proteins and changes in the density and morphology of dendritic 
spines that may constitute the primary cause for the synaptic inhibition and memory impairments.
Synaptic deficits and synapse loss occur early in AD and MCI, before the onset of plaques, being some of 
the first signs of the neurodegenerative process60,61. As Aβ aggregates it can adopt different shapes such as fibrils 
and non-fibrillar aggregates62,63, and there is a consensus that Aβ alone is not the main mediator responsible for 
AD. However, its precise pathogenic roles, subcellular location and state are still being discussed. Here we have 
provided evidence that low intraneuronal accumulation of Aβ peptides provoked by hippocampal infusion of 
UBI-Aβ42, as well as combined intraneuronal and extracellular accumulation of Aβ provoked by BRI-Aβ42, can 
disrupt cognitive behavior, synaptic plasticity and spine morphology.
Some insights on the relationship of different amyloid structures have already been discussed64–66. Further 
studies are required to determine the roles of these AAV vectors in promoting specific Aβ isoforms. It is of great 
importance to the advancement of AD research the acknowledgment of how the available tools work, so they can 
be appropriately employed in order to provide relevant results.
Methods
infusion of vectors. Stereotaxic injection of AAV-EGFP, AAV-BRI-Aβ42 and AAV-UBI-Aβ42 into the hip-
pocampus was performed according to previously described surgical protocols67,68. Viral preps were generated as 
described previously69. Briefly, AAV vectors expressing the Aβ peptides under the control of the cytomegalovirus 
enhancer/chicken beta actin (CBA) promoter, a WPRE, and the bovine growth hormone polyA were generated 
by plasmid transfection with helper plasmids in HEK293T cells. 48 hours after transfection cells were harvested 
non-specific fluorescence for each marker were set by staining with secondary antibodies only. (d) Values 
normalized to the basal state in each experimental group, mean ± SEM. Basal vs cLTP: EGFP, *p = 0.041 (n = 6); 
AAV- BRI-Aβ42, P = 0.244 (n = 7); AAV-UBI-Aβ42, P = 0.461 (n = 6).
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and lysed in the presence of 0.5% Sodium Deoxycholate and 50U/ml Benzonase (Sigma) by freeze thawing, 
and the virus isolated using a discontinuous Iodixanol gradient, and affinity purified on a HiTrap HQ column 
(Amersham). The genomic titer of each virus was determined by quantitative PCR.
4–5-month-old male C57/BL6 mice (purchased from the Jackson Laboratory, Maine, USA) were anesthetized 
and placed in stereotaxic frame under continuous isoflurane anesthesia. Using a 10-μl Hamilton syringe and 
30-gauge needle, mice received 2-μl injections of AAV-EGFP, AAV-BRI-Aβ42 and AAV-UBI-Aβ42 (1 × 1010 
genome particles/ul) in the right and left hemispheres at the following stereotaxic coordinates: anterior-posterior 
Figure 5. Impairments in synaptic number and synaptic proteins are related to Aβ overexpression via AAV-
mediated gene transfer. (a–d) Stereological quantification showed a significant decrease in total spines for the 
AAV-BRI- Aβ42 and AAV-UBI- Aβ42 groups (67.65% ± 5.06; 43.02% ± 4.93; *p < 0.0001) when compared to 
AAV-EGFP-transfected mice. There was also a significant decrease in mushroom (BRI-Aβ42: 44.09% ± 4.83; 
UBI-Aβ42: 40.13% ± 9.78; *p = 0.0021), stubby (BRI-Aβ42: 62.34% ± 4.20, *p = 0.0015) and filopodia-like 
spines (BRI-Aβ42: 76.72% ± 0.59; UBI-Aβ42: 62.53% ± 8.42; *p < 0.0001) compared to the number observed 
in EGFP-transfected mice. Notably, there was no significant difference in stubby spines in the AAV-UBI-Aβ42 
group. The values represent the mean ± SEM (n = 5 per group). (e) Light microscopic 3D reconstruction 
images of dendritic spines in the CA1 subfield in AAV-EGFP, AAV-BRI- Aβ42 and AAV-UBI- Aβ42 mice. 
(f–i) Immunoblot analysis of hippocampal homogenates of 8–9 month-old mice, normalized to GAPDH 
and expressed as arbitrary units, showing a significant reduction in the expression of PSD-95 (BRI-Aβ42: 
37.20% ± 9.19; UBI-Aβ42: 44.80% ± 5.35; *p = 0.0028), synaptophysin (BRI-Aβ42: 43.69% ± 9.75; UBI-Aβ42: 
39.82% ± 6.46; *p = 0.0030) and profilin-1 (BRI-Aβ42: 51.87% ± 8.00; UBI-Aβ42: 42.04% ± 11.13; *p = 0.0075) 
compared to the EGFP group. Quantification of western blots was performed via densitometric analysis and is 
presented as arbitrary units, normalized to GAPDH. Colored circles represent the groups tested: white - EGFP; 
yellow - BRI-Aβ42; blue - UBI-Aβ42. Values represent the mean ± SEM (n = 4 per group).
8Scientific RepoRtS |         (2019) 9:15936  | https://doi.org/10.1038/s41598-019-52324-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
(AP) −2.06 mm; dorsoventral (DV) −1.95 mm; mediolateral (ML) ± 1.75 mm. Animals were allowed to recover 
on a heating pad before being placed back in their home cages. All animal procedures are in accordance with 
National Institutes of Health and University of California guidelines and were approved by the Use Committee at 
the University of California, Irvine.
cell culture. Primary hippocampal neurons were collected from postnatal day 0 C57BL/6 J mice. Cells were 
grown and fed twice a week with Neurobasal media with antibiotics and supplemented with GlutaMAX and B-27 
(ThermoFisher Scientific). For experiments presented in Fig. 1a, cells were incubated for 24 h with AAV-EGFP, 
AAV-BRI-Aβ42 ([1] 4.7 × 1010 genome particles/ml, [2] 9.3 × 1010 genome particles/ml, [3] 2.8 × 1011 genome 
particles/ml) and AAV-UBI-Aβ42 ([1] 1.5 × 1010 genome particles/ml, [2] 7.7 × 1010 genome particles/ml, [3] 
4.6 × 1011 genome particles/ml) and the media was collected and analyzed for Aβ42 levels with a sandwich ELISA 
system as described previously70. For experiments presented in Fig. 1b,c, cells were transduced with AAV-EGFP 
7.6 × 1010 genome particles/ml, AAV-BRI-Aβ42 2.2 × 1011 genome particles/ml, and AAV-UBI-Aβ 1.6 × 1012 
genome particles/ml. 72 h later, media was collected for analysis and cells were washed with ice-cold PBS. Then, 
M-PER complemented with proteases and phosphatases inhibitors (ThermoFisher Scientific) was added and 
cells were scrapped. Media and lysates were centrifuged at 12,000xg for 10 min at 4 °C. Protein concentration in 
the lysates was determined using a commercial Bradford assay (Biorad). Media and cell lysates were analyzed for 
high molecular Aβ oligomers using an ELISA kit (Wako, cat# 298–80101) following the manufacturer’s protocol.
Aβ derived diffusible ligand (ADDL) preparation. ADDLs were prepared according to previous publi-
cations71. Briefly, Aβ1–42 was dissolved in hexafluoro-2-propanol (HFIP) and aliquoted to microcentifuge tubes. 
HFIP was removed by evaporation under vacuum and an aliquot of Aβ42 was dissolved in anhydrous dimethyl 
sulfoxide (DMSO), which was then added to ice-cold F12 medium without phenol red. This solution was incu-
bated at 4 °C for 24 h and then centrifuged at 14 000 g for 10 min. Centrifugation produced a small pellet and the 
supernatant is defined as the ADDL preparation, which comprises fibril-free solutions of oligomers as well as 
monomers. Cells were incubated with 10 mM ADDLs for 24 h.
Morris Water Maze. Three months after infusion of vectors, behavioral analyses were performed. Mice were 
trained to swim to a circular clear Plexiglas platform submerged 1.5 cm beneath the water’s surface. Four trials 
were performed per day, for 60 seconds each with 5 minutes between trials. Mice were trained for as many days as 
needed for the group to reach the training criterion of 25 seconds. The probe test was assessed 24 hours after the 
last trial, with the platform removed. Performance was monitored with the EthoVision XT video-tracking system 
(Noldus Information Technology, Leesburg, VA, USA).
contextual fear conditioning. During training, mice were placed in the fear conditioning chamber 
and allowed to explore for 2 minutes before receiving three electric foot shocks (duration: 1 s, intensity: 0.2 mA, 
intershock interval: 2 minutes). Animals were returned to the home cage 30 seconds after the last foot shock. 
Twenty-four hours later, behavior in the conditioning chamber was video recorded for 5 minutes and subse-
quently analyzed for freezing behavior.
fluorescence analysis of single-synapse long-term potentiation (fASS-Ltp). Activity-dependent 
responses in hippocampal synaptosomes were analyzed by FASS-LTP, as previously described26,27. FASS-LTP 
consists of chemical LTP (cLTP) stimulation directly in crude P2 synaptosomal fractions, immunofluorescence 
labeling for surface GluA1 and neurexin-1β, and flow cytometry analysis. Briefly, fresh crude synaptosome P2 
fractions were obtained from the hippocampi of mice injected with AAVs and stimulated with glycine (500 μM) 
and KCl (50 mM). For surface immunolabeling, primary antibodies were rabbit anti-GluA1 (Cell Signaling 
#13185; 1:400) and mouse anti-Nrx1β (UC Davis/NIH NeuroMab Facility, 75–216; 2.5 μg/ml). Secondary anti-
bodies were anti-rabbit-Alexa-405, anti-rabbit-Alexa-488 and anti-mouse-Alexa-647 antibodies (Life Sciences), 
at 2.5 μl/ml. Samples were protected from light, maintained at 4 °C and immediately run on a flow cytometer 
(Novocyte, ACEA Biosciences, Inc); 20,000 events were collected and analyzed for each sample with an event rate 
of approximately 500/sec. Analysis was performed using the FlowJo v10.3 software (LLC).
Golgi staining. Following transcardial perfusion with 0.1 M phosphate-buffered saline (PBS, pH 7.4), mice brains 
were removed and processed using a superGolgi Kit (Bioenno Tech LLC, Santa Ana, CA), as described previously24,72
Dendritic and spine analysis. Stereological quantifications were performed using Neurolucida software 
from Microbrightfield Bioscience (MBF Bioscience, Williston, VT, USA) to determine the number of spines in the 
stratum radiatum (SR) and the molecular layer (ML) of the hippocampal CA1 region, respectively. Briefly, every 
second section was used through the entire antero-posterior extent of the hippocampus (between −1.46 mm 
anterior and −3.40 mm posterior to Bregma according to Franklin and Paxinos, Third Edition, 2007). The SR and 
ML in the CA1 region were defined using a 5x objective and spines were counted using a 100x/1.4 objective. The 
coefficient of error (CE) value for each animal ranged between 0.03 and 0.08. Dendritic spine length was traced 
using a 100x/1.4 objective and data were analysed via Neurolucida Explorer software. For dendritic morphologi-
cal analysis, 5 neurons per animal (n = 6) in the CA1 hippocampal area were traced using Neurolucida software. 
Dendritic width was measured using Image J software in electronic microscopic images (10 images per animal 
for a total of 6 mice per group).
immunoblotting. Equal amounts of protein (30 μg) were separated on 10% Bis-Tris gel (Invitrogen, 
Carlsbad, CA), and transferred to nitrocellulose membranes that were blocked in a 5% (w/v) suspension of Bovine 
Serum Albumin (BSA; Gemini Bio-Products, West Sacramento, CA, USA) in 0.2% Tween 20 Tris-buffered saline 
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(TBS-T, pH 7.5) for 1 h. Next, membranes were incubated overnight at 4 °C with the following primary anti-
bodies: synaptophysin 1:1000 (Abcam, Cambridge, UK), PSD-95 1:1000 (Abcam, Cambridge, UK), profilin-1 
1:1000 (Abcam, Cambridge, UK) and GAPDH 1:1000 (Santa Cruz Biotechnology, CA, USA). Membranes were 
then washed in Tween-TBS for 20 min and incubated with specific secondary antibodies at a dilution of 1:10,000 
(Pierce Biotechnology) for 60 min. Immunocomplexes were visualized using Super Signal (ThermoFisher 
Scientific, Rockford, IL, USA) and band density measurements were made using ImageJ imaging software ver-
sion 1.36b (NIH).
immunohistochemistry. For immunohistochemistry, sections (40μm thick) were pretreated with 3% 
H2O2/3% methanol in Tris-buffered saline (TBS) for 30 min, followed by a TBS wash. Sections were then incu-
bated in TBS with 0.1% Triton X-100 (TBST) for 15 min, followed by TBST with 2% BSA (Sigma-Aldrich) for 
30 min. Sections were incubated with anti-6E10 (1:1000; Biolegend, San Diego, CA, USA) in TBS + 5% normal 
horse serum overnight at 40 C. Sections were then incubated with the appropriate secondary biotinylated anti-
body (1:500) in TBS containing 2% BSA plus 5% normal serum for 1 hour at room temperature, followed by 
Vector ABC Kit and DAB reagents (Vector Laboratories, Burlingame, CA, USA) to visualize staining.
electrochemiluminescence-linked immunoassay. Quantitative biochemical analyses of 
human Aβ and inflammatory cytokines in mouse tissue were performed using a commercially available 
electrochemiluminescence-linked immunoassay from Meso Scale Discovery (MSD, Gaithersburg, MD, USA). 
The V-PLEX Aβ Peptide Panel 1 (6E10) was used and plates were analyzed on the MS2400 imager (MSD). Assays 
were performed according to the manufacturer’s instructions, and all standards and samples were measured in 
duplicate.
enzyme-linked immunosorbent assay for Aβ42. Aβ1–42 was measured in the primary neuronal hip-
pocampus cell culture medium using a sensitive sandwich enzyme-linked immunosorbent assay system as pre-
viously described70.
Statistical analysis. All data between two groups were analyzed by Student’s t-test comparisons, and one- 
or two-way analysis of variance (ANOVA), followed by Bonferroni’s test for comparisons among more than 2 
groups. Mann-Whitney U Test was used for the FASS-LTP data. Graphpad Prism software (Graphpad Prism 
Inc., San Diego, CA, USA) was used, and the significance was set at 95% of confidence. Values are presented as 
mean ± SEM.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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